Osteotropic effects by the neuropeptides calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.

Immunohistochemical phenotypic characterization of skeletal nerve fibers has demonstrated the expression of a restricted number of neuropeptides, including calcitonin gene-related peptide (CGRP), substance P (SP) and vasoactive intestinal peptide (VIP). According to the neuro-osteological hypothesis, such neuropeptides can be released and exert paracrine biological effects on bone cells present close to the nerve endings expressing these signaling molecules. The existence of such interplay is most convincingly shown by the hypothalamic control of bone formation, in the case of leptin stimulation of hypothalamic nuclei mediated by the sympathetic nervous system and inhibitory beta-adrenergic receptors on osteoblasts. In addition to these receptors, osteoblasts and osteoclasts express functional receptors for CGRP, SP and VIP, which can regulate both bone formation and bone resorption. The evidence for these observations is summarized in the present paper.

[1]  T. Martin,et al.  Principles of Bone Biology, 3rd ed. , 2009, American Journal of Neuroradiology.

[2]  U. Lerner,et al.  Expression of the calcitonin receptor, calcitonin receptor‐like receptor, and receptor activity modifying proteins during osteoclast differentiation , 2008, Journal of cellular biochemistry.

[3]  L. Dai,et al.  Changes of substance P-immunoreactive nerve fiber innervation density in the sublesional bones in young growing rats at an early stage after spinal cord injury , 2008, Osteoporosis International.

[4]  U. Lerner,et al.  Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms. , 2007, The Journal of endocrinology.

[5]  L. Dai,et al.  Substance P and its receptors in bone metabolism , 2007, Neuropeptides.

[6]  A. Stark,et al.  Site‐specific CGRP innervation coincides with bone formation during fracture healing and modeling: A study in rat angulated tibia , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[7]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[8]  G. Saxler,,et al.  Polyethylene Particle-Induced Bone Resorption in Substance P-Deficient Mice , 2007, Calcified Tissue International.

[9]  T. Goto,et al.  Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors , 2007, Neuropeptides.

[10]  M. Palkovits,et al.  Attenuated pseudorabies virus-evoked rapid innate immune response in the rat brain , 2006, Journal of Neuroimmunology.

[11]  C. Kovacs,et al.  Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. , 2006, Endocrinology.

[12]  K. Rabe,et al.  Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. , 2006, European journal of pharmacology.

[13]  U. Lerner,et al.  Increased expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1 and C/EBP, but not NF-kappaB, in mouse calvarial osteoblasts. , 2005, Bone.

[14]  U. Lerner,et al.  The neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. , 2005, Biochemical and biophysical research communications.

[15]  C. Martínez,et al.  Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis , 2005, Arthritis research & therapy.

[16]  又吉 誉章 Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells , 2005 .

[17]  Masaki Noda,et al.  Leptin regulation of bone resorption by the sympathetic nervous system and CART , 2005, Nature.

[18]  S. Sohn Substance P upregulates osteoclastogenesis by activating nuclear factor kappa B in osteoclast precursors , 2005, Acta oto-laryngologica.

[19]  N. Hanai,et al.  Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection. , 2005, Journal of molecular endocrinology.

[20]  I. Gozes,et al.  Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. , 2004, Best practice & research. Clinical endocrinology & metabolism.

[21]  R. Emeson,et al.  Decreased Bone Formation and Osteopenia in Mice Lacking α‐Calcitonin Gene‐Related Peptide , 2004 .

[22]  T. Guo,et al.  Capsaicin‐Sensitive Sensory Neurons Contribute to the Maintenance of Trabecular Bone Integrity , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  M. de Vernejoul,et al.  RAMPs and CRLR expressions in osteoblastic cells after dexamethasone treatment. , 2004, Biochemical and biophysical research communications.

[24]  R. Lefebvre,et al.  Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. , 2004, Current pharmaceutical design.

[25]  T. Nagata,et al.  Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. , 2004, Journal of periodontology.

[26]  D. Pozo,et al.  The Significance of Vasoactive Intestinal Peptide in Immunomodulation , 2004, Pharmacological Reviews.

[27]  C. Laplace,et al.  Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo , 2004, The Journal of cell biology.

[28]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[29]  A. Bradley,et al.  Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. , 2002, The Journal of clinical investigation.

[30]  E. Goetzl,et al.  Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide , 2002, Regulatory Peptides.

[31]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[32]  A. Couvineau,et al.  Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP , 2002, Regulatory Peptides.

[33]  Y. Matsusue,et al.  Neuronal regulation of bone metabolism and anabolism: Calcitonin gene‐related peptide‐, substance P‐, and tyrosine hydroxylase‐containing nerves and the bone , 2002, Microscopy research and technique.

[34]  Teruo Tanaka,et al.  Tachykinins and tachykinin receptors in bone , 2002, Microscopy research and technique.

[35]  Patrick M. Sexton,et al.  International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.

[36]  G. Thomas,et al.  Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.

[37]  I. Reid,et al.  Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. , 2001, Bone.

[38]  Z. Dąbrowski,et al.  Effect of the neuropeptide substance P on the rat bone marrow‐derived osteogenic cells in vitro , 2001, Journal of cellular biochemistry.

[39]  J. Fahrenkrug Gut/brain peptides in the genital tract: VIP and PACAP , 2001, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[40]  H. Cooke Neurotransmitters in Neuronal Reflexes Regulating Intestinal Secretion , 2000, Annals of the New York Academy of Sciences.

[41]  M. Pondel,et al.  Calcitonin and calcitonin receptors: bone and beyond , 2000, International journal of experimental pathology.

[42]  P. Lehenkari,et al.  Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. , 2000, Bone.

[43]  Shiaoping C. Zhu,et al.  A Glia-Derived Signal Regulating Neuronal Differentiation , 2000, The Journal of Neuroscience.

[44]  U. Lerner,et al.  Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. , 2000, Biochemical and biophysical research communications.

[45]  H. Taniguchi,et al.  The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. , 2000, Biochemical and biophysical research communications.

[46]  P. Bergmann,et al.  Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders?☆ , 2000, Peptides.

[47]  Arndt F Schilling,et al.  Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.

[48]  I. Gozes,et al.  Vasoactive Intestinal Peptide: Link between Electrical Activity and Glia‐mediated Neurotrophism , 1999, Annals of the New York Academy of Sciences.

[49]  K. Smans,et al.  Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules , 1999, Regulatory Peptides.

[50]  K. Kataoka,et al.  Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. , 1999, Biochemical and biophysical research communications.

[51]  I. Reid,et al.  Comparison of the Effects of Calcitonin Gene‐Related Peptide and Amylin on Osteoblasts , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  R. Flavell,et al.  Targeted Expression of Calcitonin Gene‐Related Peptide to Osteoblasts Increases Bone Density in Mice , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  T. Tanaka,et al.  Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone , 1998, Cell and Tissue Research.

[54]  C. Shih,et al.  Neurogenic Substance P Stimulates Osteogenesis In Vitro , 1997, Peptides.

[55]  T. Nagatsu,et al.  Expression of mRNAs for neuropeptide receptors and β-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells , 1997, Neuroscience Letters.

[56]  K. Matsumoto,et al.  Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. , 1997, Endocrinology.

[57]  E. Greenfield,et al.  Stimulation by Parathyroid Hormone of Interleukin-6 and Leukemia Inhibitory Factor Expression in Osteoblasts Is an Immediate-early Gene Response Induced by cAMP Signal Transduction (*) , 1996, The Journal of Biological Chemistry.

[58]  C. Kovacs,et al.  Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells. , 1996, The Journal of endocrinology.

[59]  R. Chole,et al.  A mechanism for sympathectomy-induced bone resorption in the middle ear. , 1995, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[60]  T. Bonner,et al.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.

[61]  M. Ransjö,et al.  Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines , 1994, Calcified Tissue International.

[62]  I. Owan,et al.  The role of calcitonin gene-related peptide (CGRP) in macrophages: the presence of functional receptors and effects on proliferation and differentiation into osteoclast-like cells. , 1994, Bone and mineral.

[63]  S. Goldring,et al.  Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family , 1993, Trends in Endocrinology & Metabolism.

[64]  S. Santavirta,et al.  Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling , 1993, Neuroscience.

[65]  M. Zaidi,et al.  Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts , 1993, Experimental physiology.

[66]  I. Owan,et al.  Mechanism of action of amylin in bone , 1992, Journal of cellular physiology.

[67]  M. Schultzberg,et al.  Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR‐106–01, ROS 17/2.8, MC3T3‐E1, and Saos‐2) and primary bone cells , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[68]  T. Martin,et al.  Structure‐activity relationships in calcitonin gene‐related peptide: Cyclic AMP response in a preosteoblast cell line (ks‐4) , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[69]  M. Zaidi,et al.  Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide-(Val8Phe37). , 1991, Biochemical and biophysical research communications.

[70]  R. Elde,et al.  Distribution of CGRP-, VIP-, DβH-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat , 1991, Cell and Tissue Research.

[71]  T. Martin,et al.  Effects of calcitonin gene‐related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[72]  L. Terenius,et al.  Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. , 1988, Journal of the autonomic nervous system.

[73]  M. Schultzberg,et al.  Substance P- and CGRP-immunoreactive nerves in bone , 1988, Peptides.

[74]  G. Mundy,et al.  Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro. , 1986, Endocrinology.

[75]  K. Torizuka,et al.  Human calcitonin gene-related peptide possesses weak inhibitory potency of bone resorptionin vitro , 1986, Calcified Tissue International.

[76]  E. Hohmann,et al.  Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. , 1986, Science.

[77]  T. Martin,et al.  Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01) , 1986, Calcified Tissue International.

[78]  G. Roodman,et al.  1,25-Dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[79]  H. Morris,et al.  The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP) , 1984, Neuropeptides.

[80]  L. McManus,et al.  Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells , 1984, The Journal of cell biology.

[81]  E. Hohmann,et al.  Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells. , 1984, Endocrinology.

[82]  E. Hohmann,et al.  Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 3',5'-monophosphate-dependent mechanism. , 1983, Endocrinology.

[83]  R. Rosenberg,et al.  Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. , 1976, Science.

[84]  V. Mutt,et al.  Structure of the Porcine Vasoactive Intestinal Octacosapeptide , 1974 .

[85]  S. Said,et al.  Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasoactive intestinal peptide. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[86]  V. Mutt,et al.  Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. , 1972, European journal of biochemistry.

[87]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[88]  V. Mutt,et al.  Long Acting Vasodilator Peptide from Lung Tissue , 1969, Nature.

[89]  U. Lerner,et al.  Kinins and Neuro-osteogenic Factors , 2008 .

[90]  U. Lerner Deletions of genes encoding calcitonin/alpha-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone. , 2006, Journal of musculoskeletal & neuronal interactions.

[91]  R. Henning,et al.  Vasoactive intestinal peptide: cardiovascular effects. , 2001, Cardiovascular research.

[92]  P. Lehenkari,et al.  Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. , 2001, Endocrinology.

[93]  Vasoactive intestinal peptide prevents experimental arthritis , 2001 .

[94]  P. Lehenkari,et al.  Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase-Activating Peptide Receptor Subtypes in Mouse Calvarial Osteoblasts: Presence of VIP-2 Receptors and Differentiation-Induced Expression of VIP-1 Receptors * * The present study was supported by grants from the Swedish Medical Research C , 2001, Endocrinology.

[95]  A. Kreicbergs,et al.  Sensory nerves in the interface membrane of aseptic loose hip prostheses. , 1998, The Journal of bone and joint surgery. British volume.

[96]  O. Kozawa,et al.  Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells. , 1994, Cellular signalling.

[97]  純也 鹿志村 Pituitary adenylate cyclase activating polypeptide(PACAP)のラット膵外分泌機能に対する作用 : ラット遊離膵腺房における,PACAPの作用,その作用機序,結合部位に関する検討 , 1994 .

[98]  Y. Oiso,et al.  Pituitary adenylate cyclase-actviating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells , 1994 .

[99]  M. Zaidi,et al.  Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating intracellular Ca2+ mobilization and cell retraction. , 1993, The Journal of endocrinology.

[100]  S. Santavirta,et al.  Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus and bone. , 1992, International journal of tissue reactions.

[101]  B. Roos,et al.  Evaluation of the in vivo and in vitro calcium-regulating actions of noncalcitonin peptides produced via calcitonin gene expression. , 1986, Endocrinology.

[102]  V. Mutt,et al.  Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. , 1974, European journal of biochemistry.